Ray McDermott

Research interests

Publications

• Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

  European Urology · 2024 · https://doi.org/10.1016/j.eururo.2024.09.017

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2023 · 10.1016/s1470-2045(23)00469-2

• Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

  European Urology · 2023 · 10.1016/j.eururo.2023.06.006

• Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

  ˜The œLancet. Gastroenterology & hepatology · 2023 · 10.1016/s2468-1253(23)00243-1

• Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

  Journal of Clinical Oncology · 2023 · 10.1200/jco.23.00233

• Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2214676

• Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00367-1

• Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

  Annals of Oncology · 2022 · 10.1016/j.annonc.2022.06.008

• Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

  European Journal of Endocrinology · 2022 · 10.1530/eje-21-1259

• Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2034442

• Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00152-2

• Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30436-8

• Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.01035

• Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

  Clinical Cancer Research · 2020 · 10.1158/1078-0432.ccr-20-0394

• Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30856-3

• Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903835

• Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1816714

• Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

  The Lancet · 2018 · 10.1016/s0140-6736(18)31257-1

• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1712126

• Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.9901

• Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.73.5324

• Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30422-9

• Circular RNAs: Biogenesis, Function and Role in Human Diseases

  Frontiers in Molecular Biosciences · 2017 · 10.3389/fmolb.2017.00038

• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1510665

• 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(12)70537-5

• Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes

  PLoS ONE · 2012 · 10.1371/journal.pone.0050999

• Birbeck Granules Are Subdomains of Endosomal Recycling Compartment in Human Epidermal Langerhans Cells, Which Form Where Langerin Accumulates

  Molecular Biology of the Cell · 2002 · 10.1091/mbc.01-06-0300

Current projects

No projects listed.